GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (XTER:SRT) » Definitions » Peter Lynch Fair Value

Sartorius AG (XTER:SRT) Peter Lynch Fair Value : €54.33 (As of May. 05, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Sartorius AG Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Sartorius AG's PEG is 1. Sartorius AG's 5-Year TTM EBITDA Growth Rate is 25. Sartorius AG's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €2.17. Therefore, the Peter Lynch Fair Value for today is €54.33.

As of today (2024-05-05), Sartorius AG's share price is €223.00. Sartorius AG's Peter Lynch fair value is €54.33. Therefore, Sartorius AG's Price to Peter Lynch Fair Value Ratio for today is 4.10.


The historical rank and industry rank for Sartorius AG's Peter Lynch Fair Value or its related term are showing as below:

XTER:SRT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.35   Med: 3.05   Max: 8.65
Current: 4.1


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Sartorius AG was 8.65. The lowest was 1.35. And the median was 3.05.


XTER:SRT's Price-to-Peter-Lynch-Fair-Value is ranked worse than
84.13% of 189 companies
in the Medical Devices & Instruments industry
Industry Median: 1.69 vs XTER:SRT: 4.10

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Sartorius AG Peter Lynch Fair Value Historical Data

The historical data trend for Sartorius AG's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Peter Lynch Fair Value Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.10 39.89 109.13 247.45 75.08

Sartorius AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 206.45 180.70 128.70 75.08 54.33

Competitive Comparison of Sartorius AG's Peter Lynch Fair Value

For the Medical Instruments & Supplies subindustry, Sartorius AG's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Sartorius AG's Price-to-Peter-Lynch-Fair-Value falls into.



Sartorius AG Peter Lynch Fair Value Calculation

Sartorius AG's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *2.173
=54.33

Sartorius AG's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.17.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Sartorius AG  (XTER:SRT) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

Sartorius AG's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=223.00/54.33
=4.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG (XTER:SRT) Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.